Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director | May 19, 2022 | May 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date May 19, 2022 · Filed May 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 455,309 |
Reported balance
After 2022-05-19 transaction · row 1
1 source rowRow 1 · 2022-05-19 · Grant · Acquired 455,309 · Balance 455,309 F1: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy Philip S. Low Revocable Trust | 63,974 |
Reported balance
After 2022-05-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-05-19 · Grant · Acquired 63,974 · Balance 63,974 F1: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2032-05-18 | Direct | 22,058 |
Reported balance
After 2022-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-19 · Grant · Acquired 22,058 · Balance 22,058 F2: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
F2: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENDOCYTE INC
Report date December 21, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-12-21 · Disposition to issuer · Disposed 349,944 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2018-12-21 · Disposition to issuer · Disposed 4,375 · Balance 0 F2: This restricted stock unit ("RSU") award, which originally consisted of 8,750 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2018-12-21 · Disposition to issuer · Disposed 13,125 · Balance 0 F3: This RSU award, which originally consisted of 17,500 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2018-12-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2018-12-21 · Disposition to issuer · Disposed 22,500 · Balance 0 F5: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse Trust | 0 |
Reported balance
After 2018-12-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-12-21 · Disposition to issuer · Disposed 132,473 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.82 · Expires 2020-02-11 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-21 · Disposition to issuer · Disposed 13,570 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2021-04-14 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-21 · Disposition to issuer · Disposed 8,560 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.80 · Expires 2021-05-26 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-12-21 · Disposition to issuer · Disposed 17,950 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-12-21 · Disposition to issuer · Disposed 59,996 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.86 · Expires 2023-02-19 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-12-21 · Disposition to issuer · Disposed 56,918 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.11 · Expires 2024-02-06 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-12-21 · Disposition to issuer · Disposed 36,000 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2025-02-04 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-12-21 · Disposition to issuer · Disposed 52,498 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-12-21 · Disposition to issuer · Disposed 52,498 · Balance 0 F7: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2027-02-02 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-12-21 · Disposition to issuer · Disposed 35,000 · Balance 0 F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2028-02-08 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-12-21 · Disposition to issuer · Disposed 45,000 · Balance 0 F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
F2: This restricted stock unit ("RSU") award, which originally consisted of 8,750 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F3: This RSU award, which originally consisted of 17,500 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F4: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F5: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F7: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2017 Filed Nov 14, 2017 15:26 UTC | ENDOCYTE INC ECYT · Entity 161591 | GiftCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-014106 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,005 F1 · shares: Represents a gift of 5,600 shares to a non-profit organization, and, subsequently, there was a purchase of 5,600 shares in the open market, as reported on the next line of this Form 4. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 17:09 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-013185 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,605 F1 · shares: Represents restricted stock units that will vest and be paid 1/2 annually over a period of 2 years beginning on October 4, 2018, in the form of share of common stock for each restricted stock unit. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 19:25 UTC | ENDOCYTE INC ECYT · Entity 161591 | Tax withholdingCommon Stock | 694 | $2.18 | $1,512.92 |
DisclosureSEC source: 0001179110-17-001932 · edgar.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,605 F2 · shares: Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 1,875 restricted stock units in the form of Company common stock on a one-for-one basis on February 6, 2017. Read SEC document |
| February 04, 2017 Filed Feb 7, 2017 19:25 UTC | ENDOCYTE INC ECYT · Entity 161591 | Tax withholdingCommon Stock | 1,888 | $2.18 | $4,115.84 |
DisclosureSEC source: 0001179110-17-001932 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,299 F1 · shares: Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 2,916 and 2,187 restricted stock units in the form of Company common stock on a one-for-one basis on February 4, 2017. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 15:50 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantStock Option(right to buy) · Derivative | 35,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001179110-17-001601 · edgar.xml · derivative · entry 3 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-02-02 F2 · derivative.exercise_date: Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 15:50 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001601 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,187 F1 · shares: Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 2, 2018, in the form of one share of common stock for each restricted stock unit. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 16:01 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionStock Option(right to buy) · Derivative | 15,706 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001179110-16-031680 · edgar.xml · derivative · entry 3 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,706 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and immediately exercisable. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 16:01 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionCommon Stock | 15,706 | $2.10 | $32,982.60 |
DisclosureSEC source: 0001179110-16-031680 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.